Toxicities Conference

About the Conference Who Should Attend Key Information Registration Agenda Housing Support Accreditation

About the Conference

The conference brings together experts and thought leaders from around the world to discuss the mechanism of toxicities and symptom burden after hematopoietic cell transplantation (HCT) and cellular and gene therapies; current advances in the field; and best practices to both prevent and treat these toxicities and symptoms.

The program will include a wide range of pre-clinical, translational and clinical topics, will offer networking opportunities and a dedicated poster reception showcasing research in toxicities. This conference will be offered in-person and virtually. If you have any questions about the Toxicities Conference, please reach out to info@astct.org.

Who Should Attend

Physicians, advanced practice providers, and nurses who treat or refer patients for HCT or immune effector cell therapies.

Key Information

Topics include:

Acute, late, and potentially underrepresented toxicities of transplantation, CAR T, and gene therapies.
Enhancing health resilience and well-being in our transplantation and cellular therapy patients through nutrition, exercise science, and integrative medicine.
Novel approaches to improve the outcomes of transplantation and CAR T therapy in older patients.
New approaches incorporating machine learning for prediction and detection of toxicities to allow for earlier intervention.
Understanding the interaction between the choice GVHD prophylaxis and toxicities after allo-HCT in the era of PTCy.
Unique toxicity considerations in patients receiving cellular therapies for solid organ malignancies.

Registration

Registration rates for the in-person and virtual conference are the same, except for the in-person Trainee and Affiliate* (non-MD) and virtual Trainee Rates. Registration for the conference will close on Thursday, November 14th at 5 p.m. CT. For any registration questions, please email info@astct.org.

Register

Type	Price
Registration Rates
Residents of low and low middle income countries	$15
Member Rate	$400
Trainee/Affiliate Rate*	$150
Virtual Trainee Rate	$350
Non-Member Registration + Membership Bundle (MD/PhD)	$675
Non-Member Registration + Affiliate Membership Bundle (Non MD/PhD)	$575
Non-Member Rate	$725
Industry Rate	$850

Agenda

Day 1: Friday, November 15

6:30 AM	Registration Open
8:10 - 8:15 AM	Introduction and Welcome Remarks Sergio Giralt, MD; Memorial Sloan Kettering Cancer Center
8:15 – 9:15 AM	Keynote Lecture: What is Host Resilience, and Does it Matter? Mina Sedrak, MD, MS; UCLA Health
9:15 - 10:55 AM	Main Session 1: The Expanding Scope of Toxicities after Transplantation and Cellular and Gene Therapies Susan Prockop, MD; Boston Children’s Organizing Committee Session Chair: Christina Cho, MD; Hackensack University Medical Center
	Gene Therapy in Pediatrics and Young Adults: Challenges, Opportunities, and Safety Considerations Susan Prockop, MD; Boston Children’s
	Access to and Financial Toxicity of Transplant and Cellular Therapies Lena Winestone, MD, MSHP; UCSF Benioff Children's Hospitals
	Allogeneic Transplant in SCD Patients with ESRD Alexandra Gomez-Arteaga, MD; Weill Cornell Medicine
	Toxicities of Gene Therapies for Sickle Cell Disease Alexis Leonard, MD; St. Jude Children's Research Hospital
	Panel Discussion; Q&A
10:55 – 11:10 AM	Break
11:10 - 12:50 PM	Main Session 2: Optimizing Host Resilience Saro Armenian, DO, MPH; City of Hope Organizing Committee Session Chair: Sergio Giralt, MD; Memorial Sloan Kettering Cancer Center
	Phenotyping and Risk Characterization Prior to HCT and Cellular Therapy Saro Armenian, DO, MPH; City of Hope
	Delivery of Multidisciplinary Care Prior to and During HCT and Cellular Therapy Reena Jayani, MD; Vanderbilt University
	Unique Considerations for the Outpatient HCT and Cellular Therapy Setting Othman Salim Akhtar, MD; Medical College of Wisconsin
	Interventions to Remediate Frail Health in Transplant Survivors Kirsten Ness, PT, PhD, FAPTA; St. Jude Children's Research Hospital
	Panel Discussion; Q&A
12:50 – 1:50 PM	Lunch Break and Product Theater: What's Next for Patients with 2L+ Relapsed or Refractory Multiple Myeloma? This session is presented by Johnson & Johnson and there will be no CME offered.
1:50 - 3:30 PM	Main Session 3: Treating Older Transplantation and Cellular Therapy Recipients Mariam Nawas, MD; University of Chicago Medicine Organizing Committee Session Chair: Michael Scordo, MD, MS; Memorial Sloan Kettering Cancer Center
	Older Patients, New Approaches: Novel and Reduced Toxicity Conditioning Regimen Alternatives to Improve Outcomes Uday Popat, MD; MD Anderson Cancer Center
	Biomarkers as Measures of Fitness in HCT Recipients Ashley Rosko, MD; The Ohio State Comprehensive Cancer Center
	Using Risk Stratification Tools to Optimize and Personalize HCT in Older Adults Shannon McCurdy, MD; University of Pennsylvania
	CAR T in Older Adults: What Does it Mean to be CAR T Eligible? Mariam Nawas, MD; University of Chicago Medicine
	Panel Discussion; Q&A
3:30 – 3:45 PM	Break
3:45 - 5:25 PM	Main Session 4: Promises and Pitfalls of Emerging Technologies Roni Shouval, MD, PhD; Memorial Sloan Kettering Cancer Center Organizing Committee Session Chair: William Wood, MD, MPH; University of North Carolina at Chapel Hill
	Remote Monitoring of CAR T Patients: Experience at Mayo Clinic Yi Lin, MD, PhD; Mayo Clinic
	Patient-reported Outcomes in Cellular Therapy Rachel Cusatis, PhD; Medical College of Wisconsin
	Remote Management of Oncological Patients Sarah Wall, MD, MPH; The Ohio State Comprehensive Cancer Center
	A Multimodal Approach for Profiling and Predicting CAR T Therapy Outcome Roni Shouval, MD, PhD; Memorial Sloan Kettering Cancer Center
	Panel Discussion; Q&A
5:25 – 7:00 PM	Networking and Poster Reception

Day 2: Saturday, November 16

Housing

The Notary Hotel, Philadelphia, Autograph Collection

21 N Juniper Street
Philadelphia, PA 19107
(215) 496-3200

Registered attendees will receive the housing link to secure discounted room rates in their official registration confirmation email.

Room Rate

$259 plus any applicable taxes and fees (single/double).

Housing Rate Cutoff

To take advantage of the discounted room rate, be sure to book your reservation on or before October 31, 2024. After October 31, the room block will be released and the negotiated room rates may not be available. Please make sure the hotel is aware of any special needs. They will assign specific room types and any other requests based on availability.

Deposits

Please have your credit card information on hand upon booking your reservation. The Notary Hotel requires each individual reservation be guaranteed with a deposit equal to one night's room and tax.

Changes or Cancellations

The Notary Hotel requires that you cancel your reservation (72) hours prior to your arrival. The deposit of one night's room and tax will be forfeited for cancellations made less than (72) hours from arrival. Please call the hotel directly to make a cancellation and keep your cancellation confirmation number for your records.

Confirmations

The hotel will send you a confirmation to the email used in booking your reservation using the customized online reservation link provided by ASTCT. Review it carefully for accuracy and keep a copy for your records.

Support

Contact Angie Dahl, Director of Development, to learn more about sponsorship opportunities. Review the Toxicities Conference prospectus.

Accreditation

This activity is jointly provided by The France Foundation and the American Society for Transplantation and Cellular Therapy (ASTCT).

TARGET AUDIENCE

This educational activity is intended for physicians, advanced practice providers, and nurses who treat or refer patients for HCT or immune effector cell therapies.

STATEMENT OF NEED

The conference brings together experts and thought leaders from around the world to discuss the mechanism of toxicities and symptom burden after hematopoietic cell transplantation (HCT) and cellular and gene therapies; current advances in the field; and best practices to both prevent and treat these toxicities and symptoms.

The program will include a wide range of pre-clinical, translational and clinical topics, will offer networking opportunities and a dedicated poster reception showcasing research in toxicities.

EDUCATIONAL ACTIVITY LEARNING OBJECTIVES

Upon completion of this course, the participants should be able to:

Identify the mechanisms of the most common treatment-related toxicities after HCT, cellular and gene therapies.
Discuss the best practices in the prevention and treatment of toxicities and symptom burden after HCT, cellular and gene therapies.
Collaborate with a multidisciplinary group of colleagues to discuss, brainstorm, and plan future quality improvement and research efforts to reduce toxicities, improve the patient experience, and decrease non-relapse mortality.

ACCREDITATION STATEMENT

In support of improving patient care, this activity has been planned and implemented by The France Foundation and the American Society for Transplantation and Cellular Therapy. The France Foundation is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the health care team.

Physician Credit Designation

The France Foundation designates this live activity for a maximum of 12.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

METHOD OF PARTICIPATION/HOW TO RECEIVE CREDIT

Review the activity objectives and CME/CE information.
Participate in the CME/CE activity.
Complete the course evaluation.
If you are requesting educational credits or a certificate of participation, your certificate will be available for download.

DISCLOSURE POLICY

In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF) and the American Society for Transplantation and Cellular Therapy (ASTCT) require that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF And ASTCT resolve all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs.

Furthermore, TFF and ASTCT seek to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF and ASTCT are committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.

PLANNER, STAFF, AND FACULTY DISCLOSURES

Planner, staff, and faculty disclosures will be available at the conference.

DISCLOSURE OF UNLABELED USE:

TFF and ASTCT require CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that are outside of US Food and Drug Administration approved labeling.

This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF and ASTCT do not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

DISCLAIMER

TFF and ASTCT present this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of

their own clinical judgment and accepted standards of care. The France Foundation, ASTCT, and the commercial supporter(s) assume no liability for the information herein.

Information

If you have questions about this CME/CE activity, please contact The France Foundation at 860-434-1650 or htarbox@francefoundation.com.

7:15 – 8:15 AM	Breakfast Product Theater: Know the Subtle Signs: When to Intervene With Jakafi® (ruxolitinib) in Chronic Graft-versus-Host Disease \| A Real-World, Case-Based Discussion This session is presented by Incyte and there will be no CME offered.
8:15 AM	Day 2 Welcome
8:15 - 9:15 AM	Morning Debate: Toxicities in the Era of PTCy: Are Novel Combinations as Effective as PTCy? Brian Shaffer, MD; Memorial Sloan Kettering Cancer Center Organizing Committee Session Chair: Shernan Holtan, MD; Roswell Park Comprehensive Cancer Center
	Should the dose of PTCy be reduced? A Samer Al-Homsi, MD, MBA; Donald and Barbara Zucker School of Medicine at Northwell Hofstra University
	Alternatives to PTCy: Novel Agents Mahasweta Gooptu, MD; Dana-Farber Cancer Institute
	To the "Heart" of the Matter: Toxicities of PTCy Betty Hamilton, MD; Cleveland Clinic
9:15 – 9:30 AM	Break
9:30 - 11:10 AM	Main Session 5: Toxicities of Cellular Therapies for Solid Organ Malignancies Allison Betof Warner, MD, PhD; Stanford Medicine Organizing Committee Session Chair: Melody Smith, MD, MS; Stanford Medicine
	Head and Neck Cancers Kedar Kirtane, MD; Moffitt Cancer Center
	CAR T-cells for GBM Reena Thomas, MD, PhD; Stanford Medicine
	TIL Therapy for Melanoma and Beyond: Management and Toxicities Allison Betof Warner, MD, PhD; Stanford Medicine
	Panel Discussion; Q&A
11:10 - 11:25 AM	Break
11:25 – 12:25 PM	Keynote Lecture: Reflecting on the Past, Embracing the Future: Strategies for Collaborative Studies for Reduction of Toxicities within Our Transplant and Cellular Therapy Community Mohamed Sorror, MD, MSc; Fred Hutchinson Cancer Center
12:25 - 12:35 PM	Closing Remarks and Adjourn David Porter, MD; University of Pennsylvania

4TH INTERNATIONAL CONFERENCE ON TOXICITIES OF TRANSPLANTATION AND CELLULAR THERAPIES